New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 23, 2014
07:52 EDTISIS, CLDN, ARWR, SRPT, INO, BMRN, ALNY, SGMO, IDRA, BLUE, AGTCPiper Jaffray to hold a symposium
GenomeRX Symposium to be held in New York on June 23.
News For AGTC;ALNY;ARWR;BLUE;BMRN;CLDN;IDRA;INO;ISIS;SGMO;SRPT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
January 22, 2015
10:03 EDTARWROn the Fly: Analyst Downgrade Summary
Subscribe for More Information
09:16 EDTARWROn The Fly: Pre-market Movers
Subscribe for More Information
07:43 EDTBLUEbluebird bio reinstated with a Buy at BofA/Merrill
Subscribe for More Information
07:14 EDTARWRArrowhead downgraded to Hold from Buy at Deutsche Bank
Subscribe for More Information
06:38 EDTBMRNBioMarin 8.5M share Spot Secondary priced at $93.25
The deal size was increased to 8.5M shares from 7.25M shares. BofA/Merrill and Morgan Stanley acted as joint book running managers for the offering.
06:33 EDTARWRArrowhead downgraded to Hold from Buy at Deutsche Bank
Subscribe for More Information
January 21, 2015
18:27 EDTBMRNOn The Fly: After Hours Movers
UP AFTER EARNINGS: eBay (EBAY), up 2.9%... United Rentals (URI), up 1.5%. ALSO HIGHER: Minerva (NERV), up 16.1% after reporting positive Phase 1 data with MIN-202... Endo (ENDP), up 3.1% after it was announced that Endo will replace Covidien in S&P 500 as of 1/26 close... Covidien (COV) is up 1%. DOWN AFTER EARNINGS: F5 Networks (FFIV), down 15.8%... Xilinx (XLNX), down 6.1%... Discover Financial Services (DFS), down 3.3%... American Express (AXP), down 2.2%. ALSO LOWER: BioMarin (BMRN), down 2.5% after filing to sell 7.25M shares of common stock... Kinder Morgan (KMI), down 1.9% after announcing that it will acquire Hiland Partners for approximately $3B and reporting fourth quarter results... Cisco (CSCO), down 1.4% after Bloomberg reported that Oracle's (ORCL) Ellison said that Oracle's new Virtual Compute Appliance is cheaper than Cisco's product.
16:03 EDTBMRNBioMarin files to sell 7.25M shares of common stock
Subscribe for More Information
12:27 EDTBLUEbluebird bio price target raised to $146 from $94 at Wedbush
Subscribe for More Information
10:01 EDTSRPTOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
06:59 EDTSRPTSarepta downgraded to Neutral from Outperform at Wedbush
Subscribe for More Information
06:08 EDTALNYAlnylam 4.737M share Secondary priced at $95.00
Subscribe for More Information
January 20, 2015
13:21 EDTBLUECAR T-Cell therapy drug stocks down sharply following NY Times story
Shares of biotechnology companies that are developing chimeric antigen receptor T cells or CAR T therapy drugs are falling sharply after a New York Times story titled "Riding High, Biotech Firms Remain Wary." WHAT'S NEW: Over the weekend, the New York Times published the story that struck a cautionary tone on the CAR-T therapy drugs. In this form of cancer treatment the patients own immune system cells are genetically manipulated to battle tumors. The New York Times story noted that there were some notable outcomes in the treatment of leukemia and lymphoma with the CAR T treatments but highlighted that the "technique is still early in development and can cause severe side effects." WHAT'S NOTABLE. Early last week, Intrexon (XON) and its oncology partner, ZIOPHARM Oncology (ZIOP), announced an exclusive licensing agreement with The University of Texas MD Anderson Cancer Center, including an exclusive sub-licensing agreement through MD Anderson for intellectual property developed at the University of Minnesota for the development of non-viral adoptive cellular cancer immunotherapies. Both companies' shares were up sharply following the announcement ZIOPHARM was up around 55% and Intrexon up over 30% the day following the announcement. PRICE ACTION: Shares of drug companies in the space are sharply lower in midday trading, with ZIOPHARM Oncology and Kite Pharma (KITE) each down over 9%, Intrexon down almost 12%, and Bellicum Pharmaceutical (BLCM) and bluebird bio (BLUE) each down almost 5%. Reference Link
January 15, 2015
15:26 EDTBMRN, SRPTSarepta says no safety info or comparison in BioMarin presentation
Sarepta (SRPT) said that, given the small sample size of study 201/202, the company understood the importance of providing an "extensive amount of date" in order to understand eteplirsen's treatment effect. Sarepta has reported mITT data since week 24 and has continued to provide updates on this same mITT at every timepoint, the company said. BioMarin's (BMRN) presentation on Monday focused on extension phase and excluded dose-escalation phase and results during off-treatment periods, according to Sarepta. "Sarepta has regularly reported complete 201/202 safety data on all patients. No safety information or comparison [was included] in BioMarin's Monday presentation," Sarepta wrote in slides for its presentation at the JPMorgan Healthcare Conference.
07:13 EDTSRPTJPMorgan to hold a conference
Subscribe for More Information
05:26 EDTISISIsis receives orphan status for myotonic dystrophy drug treatment
Subscribe for More Information
January 14, 2015
08:30 EDTSRPTSarepta says first patient dosed in European Phase 1/II SRP-4053 study
Subscribe for More Information
07:19 EDTBMRNBioMarin volatility at upper end of two-year range as shares at record high
Subscribe for More Information
07:05 EDTISISIsis Pharmaceuticals earns $7M from Biogen for advancing muscular atrophy study
Subscribe for More Information
January 13, 2015
08:53 EDTBMRNProsensa announces holder approval of certain matters relating to BioMarin
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use